看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
) u/ g! \. `( ~( \+ @. {- ~% S2 M( t8 J. P/ X4 W* H7 @/ v8 U5 M; l
( c! ^$ a) ]4 W; n/ t8 |+ RCurrently available feasibility data for possible combination strategies. 2 s4 Y8 H# S0 R5 f+ p# h
————————————————————————————————$ n5 F. T0 h# ?2 _% k4 u
Combination Feasibility according to preliminary data
" K/ a) q1 k7 K0 k$ n——————————————————————————————————: R/ I. Z8 ?. k
Bevacizumab + sorafenib Yes, reduced dose
e; f: U! g5 E( [4 uBevacizumab + sunitinib† No . `0 h1 A W4 e9 v) f
Bevacizumab + temsirolimus Yes A: R8 I5 e) b7 G! M; P" u @
Bevacizumab + everolimus Yes
/ g8 ~! @" W/ \3 k# A* oSorafenib + sunitinib ? 6 L+ t: Z. N7 {5 v: {5 M
Sorafenib + temsirolimus Yes, reduced dose
* j5 R2 M' f- O) }$ B- ]5 G6 |6 N6 bSorafenib + everolimus Yes, reduced dose % n7 W- F5 p- Y' d' t( @" }
Sunitinib + temsirolimus† No
6 l% T0 w J! g( ]4 DSunitinib + everolimus ? : V7 p5 o5 g8 z3 \. a8 q* a
Temsirolimus + everolimus ? ' e% j0 U" u* W1 Z6 H# p: K
————————————————————
" a, Q' _ C* W# c2 j/ X5 y$ ^†Led to US FDA warning.+ u. \. {0 @8 v0 x; z" c
?: As yet unattempted combination.
- L3 X \( q2 a |